Predictive genetic testing for drug-induced liver injury: Considerations of clinical utility

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 3, 2012, Pages 376-380

  Alfirevic, A ^a   Pirmohamed, M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; FLUCLOXACILLIN; LAPATINIB; LEUKOCYTE ANTIGEN; LUMIRACOXIB; TICLOPIDINE; TUBERCULOSTATIC AGENT; VALPROIC ACID; WARFARIN; XIMELAGATRAN;

ACCURACY; ALLELE; ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC SCREENING; HEREDITY; HLA SYSTEM; HUMAN; LOSS OF FUNCTION MUTATION; PHARMACOGENETICS; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TOXIC HEPATITIS;

ALLELES; DRUG-INDUCED LIVER INJURY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; HLA ANTIGENS; HUMANS; SENSITIVITY AND SPECIFICITY;

EID: 84865417439     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.107     Document Type: Article

References (30)

1. Ostapowicz, G. et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137, 947-54 (2002). (Pubitemid 35440240)
2. Russo, M.W., Galanko, J.A., Shrestha, R., Fried, M.W. & Watkins, P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 10, 1018-1023 (2004). (Pubitemid 39232756)
3. Sgro, C. et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36, 451-455 (2002). (Pubitemid 34810366)
4. Lammert, C., Einarsson, S., Saha, C., Niklasson, A., Bjornsson, E. & Chalasani, N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 47, 2003-2009 (2008). (Pubitemid 351945567)
5. Reese, M. et al. An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development. Chem. Biol. Interact. 192, 60-64 (2011).
6. Aithal, G.P. et al. Case defnition and phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Ther. 89, 806-815 (2011).
7. Daly, A.K. & Day, C.P. Genetic association studies in drug-induced liver injury. Drug Metab. Rev. 44, 116-126 (2012).
8. Stewart, J.D. et al. Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 52, 1791-1796 (2010).
9. Stine, J.G. & Lewis, J.H. Drug-induced liver injury: a summary of recent advances. Expert Opin. Drug Metab. Toxicol. 7, 875-890 (2011).
10. Daly, A.K. et al. HLA-B 5701 genotype is a major determinant of drug-induced liver injury due to fucloxacillin. Nat. Genet. 41, 816-819 (2009).
11. Donaldson, P.T. et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J. Hepatol. 53, 1049-1053 (2010).
12. Lucena, M.I. et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is infuenced by multiple HLA class I and II alleles. Gastroenterology 141, 338-347 (2011).
13. Singer, J.B. et al. A genome-wide study identifes HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 42, 711-714 (2010).
14. Ariyoshi, N. et al. Enhanced susceptibility of HLA-mediated ticlopidine-induced idiosyncratic hepatotoxicity by CYP2B6 polymorphism in Japanese. Drug Metab. Pharmacokinet. 25, 298-306 (2010).
15. Hirata, K. et al. Ticlopidine-induced hepatotoxicity is associated with specifc human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 8, 29-33 (2008).
16. Kindmark, A. et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8, 186-195 (2008). (Pubitemid 351712643)
17. Sharma, S.K., Balamurugan, A., Saha, P.K., Pandey, R.M. & Mehra, N.K. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am. J. Respir. Crit. Care Med. 166, 916-919 (2002). (Pubitemid 35193218)
18. Spraggs, C.F. et al. HLA-DQA1 02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol. 29, 667-673 (2011).
19. Testa, L., Bhindi, R., Agostoni, P., Abbate, A., Zoccai, G.G. & van Gaal, W.J. The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk beneft profle. Expert Opin. Drug Saf. 6, 397-406 (2007). (Pubitemid 351308168)
20. Hendrick, R.E. & Helvie, M.A. Mammography screening: a new estimate of number needed to screen to prevent one breast cancer death. AJR. Am. J. Roentgenol. 198, 723-728 (2012).
21. Hessels, D. & Schalken, J.A. The use of PCA3 in the diagnosis of prostate cancer. Nat. Rev. Urol. 6, 255-261 (2009).
22. Mallal, S. et al. HLA-B 5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008). (Pubitemid 351214284)
23. Aithal, G.P., Rawlins, M.D. & Day, C.P. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ 319, 1541 (1999).
24. Rockey, D.C. et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 51, 2117-2126 (2010).
25. Andrade, R.J., Camargo, R., Lucena, M.I. & González-Grande, R. Causality assessment in drug-induced hepatotoxicity. Expert Opin. Drug Saf. 3, 329-344 (2004). (Pubitemid 39023082)
26. Miljkovic, M.M., Dobric, S. & Dragojevic-Simic, V. Consistency between causality assessments obtained with two scales and their agreement with clinical judgments in hepatotoxicity. Pharmacoepidemiol. Drug Saf. 20, 272-285 (2011).
27. Rochon, J. et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 48, 1175-1183 (2008).
28. Hari, Y. et al. T cell involvement in cutaneous drug eruptions. Clin. Exp. Allergy 31, 1398-1408 (2001). (Pubitemid 32823877)
29. Keisu, M. & Andersson, T.B. Drug-induced liver injury in humans: the case of ximelagatran. Handb. Exp. Pharmacol. 407-418 (2010).
30. Chen, R. et al. Personal omics profling reveals dynamic molecular and medical phenotypes. Cell 148, 1293-1307 (2012).